

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NEOGENESIS PHARMACEUTICALS, INC.	02/14/2005
RECEIVING PARTY DATA	
Name:	SCHERING CORPORATION
Street Address:	2000 GALLOPING HILL ROAD
City:	KENILWORTH
State/Country:	NEW JERSEY
Postal Code:	07033
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10126122
CORRESPONDENCE DATA	
Fax Number:	(908)298-5388
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	908-298-5255
Email:	shawn.m.armstrong@spcorp.com
Correspondent Name:	SCHERING-PLOUGH CORPORATION
Address Line 1:	2000 GALLOPING HILL ROAD
Address Line 2:	K-6-1, 1990
Address Line 4:	KENILWORTH, NEW JERSEY 07033
ATTORNEY DOCKET NUMBER:	NE06302US03
NAME OF SUBMITTER:	SHAWN ARMSTRONG
Total Attachments: 9 source=NEO6302US03#page1.tif source=NEO6302US03#page2.tif source=NEO6302US03#page3.tif	

CH \$40.00 10126122

500143573

PATENT  
REEL: 018175 FRAME: 0369

source=NEO6302US03#page4.tif  
source=NEO6302US03#page5.tif  
source=NEO6302US03#page6.tif  
source=NEO6302US03#page7.tif  
source=NEO6302US03#page8.tif  
source=NEO6302US03#page9.tif

## PATENT ASSIGNMENT

The parties to this Patent Assignment, dated as of February 14, 2005, are (i) NeoGenesis Pharmaceuticals, Inc. (the "Assignor"), a Delaware corporation with a principal place of business at 840 Memorial Drive, Cambridge, MA 02139, and (ii) Schering Corporation (the "Assignee"), a New Jersey corporation with a principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033.

WHEREAS, Assignor is the owner of (i) the patents identified in Exhibit A attached hereto and the inventions disclosed therein (the "U.S. Patents"), (ii) the patent applications identified in Exhibit A attached hereto and the inventions disclosed therein (the "U.S. Patent Applications"), (iii) the patents identified in Exhibit B attached hereto and the inventions disclosed therein (the "Foreign Patents", and together with the U.S. Patents, the "Patents"), and (iv) the patent applications identified in Exhibit B attached hereto and the inventions disclosed therein (the "Foreign Patent Applications" and together with the U.S. Patent Applications, the "Patent Applications");

WHEREAS, the Assignor desire to assign the Patents and the Patent Applications to the Assignee.

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee agree as follows:

1. **Assignment.** The Assignor hereby assigns and transfers unto Assignee all of Assignor's right, title and interest in and to the Patents and the Patent Applications, together with the right to sue and recover for, and the right to profits or damages due or accrued, arising out of or in connection with, any and all past, present or future infringements of the Patents and the Patent Applications.

2. **Recordation.** In order to record this Patent Assignment with the United States Patent and Trademark Office (the "PTO"), the parties hereto shall execute this Patent Assignment, and the Assignor shall execute the Recordation Form Cover Sheet required by the PTO in order to record the assignment effected hereby. Thereafter, Assignee shall record the executed Recordation Form Cover Sheet with the PTO, together with any Schedules and Exhibits thereto, including, but not limited to, this Patent Assignment and Exhibit A hereto. In order to record this Patent Assignment with the appropriate governmental or regulatory authorities, agencies or offices of any other country ("Foreign Offices"), the parties hereto shall execute this Patent Assignment and any other agreement, document or instrument of assignment necessary and appropriate to record the assignment effected hereby in any Foreign Office.

3. **Further Assurances.** The Assignor shall, at any time and from time to time, and at its expense, make, execute, acknowledge and deliver, and file and record as necessary or appropriate with governmental or regulatory authorities, agencies or

offices (in each case, domestic or foreign), such agreements, assignments, documents and instruments, and do such other and further acts and things (including, without limitation, obtaining consents of third parties), as the Assignee may reasonably request or as may be necessary or appropriate in order to implement and effect fully the intentions, purposes and provisions of this Patent Assignment.

4. **Power Of Attorney.** The Assignor does hereby make, constitute and appoint the Assignee (and any officer or agent of the Assignee as the Assignee may select in its exclusive discretion) as the Assignor's true and lawful attorney-in-fact, with the power to endorse the Assignor's name on all applications, documents, papers and instruments necessary to implement and effect fully the intentions, purposes and provisions of this Patent Assignment, including but not limited to the filing of any instrument of assignment and documents related thereto to effect such assignment in the PTO and Foreign Offices. The Assignor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof, and releases the Assignee from any claims, liabilities, causes of action or demands arising out of or in connection with any action taken or omitted to be taken by the Assignee under this power of attorney (except for the Assignee's gross negligence or willful misconduct). This power of attorney shall be irrevocable.

*[The remainder of this page is intentionally left blank.]*

IN WITNESS WHEREOF, the Assignor has executed and delivered this Patent Assignment as an instrument under seal as of the date first written above.

NEOGENESIS PHARMACEUTICALS, INC.

By: \_\_\_\_\_  
Name: Henry B. Skinner, Ph.D.  
Title: President and Chief Executive Officer

The foregoing assignment of said Patents and Patent Applications by the Assignor to the Assignee is hereby accepted as of this \_\_\_\_ day of \_\_\_\_\_, 2005.

SCHERING CORPORATION

By: E. Kevin Moore  
Name: E. Kevin Moore  
Title: Vice President and Treasurer



IN WITNESS WHEREOF, the Assignor has executed and delivered this Patent Assignment as an instrument under seal as of the date first written above.

NEOGENESIS PHARMACEUTICALS, INC.

By: 

Name: Henry B. Skinner, Ph.D.

Title: President and Chief Executive Officer

The foregoing assignment of said Patents and Patent Applications by the Assignor to the Assignee is hereby accepted as of this \_\_\_\_ day of \_\_\_\_\_, 2005.

SCHERING CORPORATION

By: \_\_\_\_\_

Name:

Title:

Signature Page to Patent Assignment

PATENT  
REEL: 018175 FRAME: 0374

STATE OF MASSACHUSETTS )  
COUNTY OF Middlesex ) ss. )

On this 14 day of February, 2005, before me appeared Henry B. Skinner, the person who signed this instrument, who acknowledged that he is the President and Chief Executive Officer of NeoGenesis Pharmaceuticals, Inc. and that being duly authorized he signed such instrument as a free act on behalf of NeoGenesis Pharmaceuticals, Inc.

  
Notary Public

[Seal]

My commission expires:

7/7/2011



DAVID W. SKINNER  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires  
July 7, 2011

Signature Page to Patent Assignment

PATENT  
REEL: 018175 FRAME: 0375

Exhibit A  
to Patent Assignment

UNITED STATES PATENTS

Patent No.	Issue Date	Title
6,147,344	11/14/2000	Method for Identifying Compounds in a Chemical Mixture
6,207,861	3/27/2001	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
6,714,875	3/30/2004	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
6,694,267	2/17/2004	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
6,721,665	4/13/2004	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
6,581,013	6/17/2003	Method for Identifying Compounds in a Chemical Mixture
6,691,046	2/10/2004	Methods and Apparatus for Identifying Unknown Compounds in Complex Chemical Mixtures Using Mass Spectrometry and Mass Differential Analysis.



# UNITED STATES PATENT APPLICATIONS

Serial No.	Filing Date	Title
10/126,122	4/19/2002	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
10/029,009	12/19/2001	Affinity Selection-Based Screening of Hydrophobic Proteins
10/385,558	03/11/2003	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
10/386,198	03/11/2003	Method for Producing and Screening Mass-Coded Combinatorial Libraries for Drug Discovery and Target Validation
10/797,551	3/10/2004	Ligand Analysis
US04/07286 PCT	Provisional No. 60/502,710; Filed: 9/12/2003  PCT Only, US designated Filed: 03/10/2004	Heterocyclic Kinase Inhibitors: Methods Of Use And Synthesis

**Exhibit B  
to Patent Assignment**

Location	Serial Number	Title	Filed	Status
Europe	99951970.5	Method for Identifying Compounds in a Chemical Mixture	10/14/1999	Published
Japan	2000-576472	Method for Identifying Compounds in a Chemical Mixture	10/14/1999	Pending
PCT	US99/23837	Method for Identifying Compounds in a Chemical Mixture	10/14/1999	National Phase
Europe	99900730.5	Method for Producing Mass-Coded Combinatorial Libraries	01/04/1999	Published
Japan	527513/2000	Method for Producing Mass-Coded Combinatorial Libraries	01/04/1999	Published
PCT	US99/00024	Method for Producing Mass-Coded Combinatorial Libraries	01/04/1999	National Phase
Canada	2313957	Method for Producing Mass-Coded Combinatorial Libraries	07/14/2000	Pending
PCT	US01/50088	Affinity Selection-Based Screening of Hydrophobic Proteins	12/19/2001	National Phase
Australia	2002246810	Affinity Selection-Based Screening of Hydrophobic Proteins	12/19/2001	Pending
Canada	2433354	Affinity Selection-Based Screening of	12/19/2001	Pending

		Hydrophobic Proteins		
Europe	01994415.6	Affinity Selection- Based Screening of Hydrophobic Proteins	12/19/2001	Pending
Japan	2002-558022	Affinity Selection- Based Screening of Hydrophobic Proteins	12/19/2001	Pending
PCT	PCT/US2004/00 7364  Pub # WO2004/08153 1	Ligand Analysis	03/22/2004 <i>10</i>	Published
PCT	PCT/US2004/00 8805 Pub # WO2004/08561 8	Method of Screening for Target Ligands	03/22/2004	Published